Innovent Biologics (FRA:6IB) Deferred Tax : €0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Innovent Biologics's change in deferred tax for the six months ended in Dec. 2024 was €0 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Dec. 2024 was €0 Mil.

Innovent Biologics Deferred Tax Historical Data

The historical data trend for Innovent Biologics's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Deferred Tax Chart

Innovent Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Deferred Tax

Get a 7-Day Free Trial

Innovent Biologics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Deferred Tax	Get a 7-Day Free Trial												-	-	-	-	-

Innovent Biologics Deferred Tax Calculation

Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0 Mil.

Innovent Biologics Deferred Tax Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (FRA:6IB) » Definitions » Deferred Tax

Comparable Companies

Traded in Other Exchanges

IVBXF:USA IVBIY:USA 01801:Hong Kong 6IB:Germany

Address

168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.innoventbio.com

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has 12 commercialized oncology products and three commercialized nononcology products as of March 2025. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Innovent Biologics Headlines

No Headlines